MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7542
-0.0185
-2.39%
Closed 17:56 05/29 EDT
OPEN
0.7800
PREV CLOSE
0.7727
HIGH
0.7800
LOW
0.7320
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
1.440
52 WEEK LOW
0.5000
MARKET CAP
73.82M
P/E (TTM)
-1.2755
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SCYX stock price target is 5.14 with a high estimate of 10.00 and a low estimate of 3.500.

EPS

SCYX News

More
SCYNEXIS Q1 EPS $(0.070) Up From $(0.460) YoY
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.070) per share. This is a 84.78 percent increase over losses of $(0.460) per share from the same period last year.
Benzinga · 05/11 13:02
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more.
GlobeNewswire · 05/11 12:50
SCYNEXIS Highlights 6 Abstracts Published By ECCMID Related To Potential Clinical Utility Of Ibrexafungerp
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the publication of six abstracts in the 30th
Benzinga · 05/06 12:13
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal.
GlobeNewswire · 05/06 12:00
SCYNEXIS files for 19.4M common shares
SCYNEXIS (NASDAQ:SCYX) has filed a prospectus for a 19.4M common shares from stockholders. Shares up 1% after hours.
seekingalpha · 05/02 14:39
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will
GlobeNewswire · 04/28 12:00
How Does SCYNEXIS, Inc. (NASDAQ:SCYX) Affect Your Portfolio Volatility?
Simply Wall St. · 04/27 19:40
Aegis Capital Maintains Buy on SCYNEXIS, Raises Price Target to $4.5
Aegis Capital maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price target from $4 to $4.5.
Benzinga · 04/23 16:40

Industry

Pharmaceuticals
+1.26%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About SCYX

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
More

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.